Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 438Thoracic 50Gynecologic 36Breast 32Genitourinary 29Head & Neck 26Sarcoma 14Endocrine 9Dermatologic 9Other solid neoplasm 6NET 6CNS 5Plasma cell 2Other hematologic neoplasm 2Lymphoid 2Other neoplasm 1Myeloid 1

Conditions

Lymphoma 2981Precursor Cell Lymphoblastic Leukemia-Lymphoma 2496Lymphoma, Non-Hodgkin 2265Leukemia, Lymphocytic, Chronic, B-Cell 1992Lymphoma, Follicular 1847Lymphoma, Large B-Cell, Diffuse 1784Leukemia 1339Hodgkin Disease 1292Lymphoma, Mantle-Cell 1193Leukemia, Myeloid, Acute 978Burkitt Lymphoma 955Multiple Myeloma 866Lymphoma, B-Cell, Marginal Zone 853Recurrence 839Lymphoma, B-Cell 754Myelodysplastic Syndromes 682Neoplasms 593Lymphoma, T-Cell, Cutaneous 543Waldenstrom Macroglobulinemia 514Lymphoma, Large-Cell, Immunoblastic 490Mycosis Fungoides 438Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 414Lymphoma, Large-Cell, Anaplastic 390Sezary Syndrome 364Lymphoma, T-Cell, Peripheral 350Hematologic Neoplasms 350Leukemia, Myelogenous, Chronic, BCR-ABL Positive 334Myeloproliferative Disorders 328Neoplasms, Plasma Cell 309Blast Crisis 284

Interventions

IMC-001 1Antibodies 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Lymphoid × Clear all
NCT06451497 2026-04-02

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Zumutor Biologics Inc.

Phase 1 Recruiting
100 enrolled
BreastGastrointestinalGenitourinaryHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms

NCT03999658 2023-05-01

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Sorrento Therapeutics, Inc.

Phase 2 Withdrawn
GastrointestinalLymphoid

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Cholangiocarcinoma, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡